Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 2:40 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 72 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Xeomin Clear all
Completed Phase 3 Interventional Results available

Efficacy and Safety Dose Titration Study of Botulinum Toxin Type A to Treat Spasticity in the Leg and Arm

NCT01603459
View directory record Official record
Conditions
Spasticity of the Upper and Lower Limb Due to Cerebral Causes
Interventions
IncobotulinumtoxinA
Drug
Lead sponsor
Merz Pharmaceuticals GmbH
Industry
Eligibility
18 Years to 80 Years
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
6
States / cities
Doral, Florida • Indianapolis, Indiana • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2017 · Synced Oct 18, 2026, 2:40 PM EDT
Completed No phase listed Observational

Trial Evaluating Xeomin® (incobotulinumtoxinA) for Cervical Dystonia or Blepharospasm in the United States

NCT01287247
View directory record Official record
Conditions
Cervical Dystonia, Blepharospasm
Interventions
Xeomin®
Biological
Lead sponsor
Merz North America, Inc.
Industry
Eligibility
18 Years and older
Enrollment
688 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
70
States / cities
Cullman, Alabama • Scottsdale, Arizona • Tucson, Arizona + 60 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2015 · Synced Oct 18, 2026, 2:40 PM EDT
Completed Phase 4 Interventional Results available

Open-Label Non-Inferiority Study Evaluating the Efficacy and Safety of Xeomin® in Subjects With Cervical Dystonia Flex

NCT01486264
View directory record Official record
Conditions
Cervical Dystonia
Interventions
Xeomin®
Biological
Lead sponsor
Merz Pharmaceuticals GmbH
Industry
Eligibility
18 Years to 81 Years
Enrollment
283 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
43
States / cities
Birmingham, Alabama • Fountain Valley, California • Loma Linda, California + 34 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2022 · Synced Oct 18, 2026, 2:40 PM EDT
Terminated Phase 2 Interventional Results available

Incobotulinum Toxin for the Treatment of Trigeminal Neuralgia

NCT02088632
View directory record Official record
Conditions
Trigeminal Neuralgia
Interventions
Incobotulinumtoxina, Placebo Comparator
Biological · Other
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years to 75 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 28, 2023 · Synced Oct 18, 2026, 2:40 PM EDT
Active, not recruiting Phase 3 Interventional

Study to Compare the Efficacy and Safety of NT 201 (Botulinum Toxin) With Placebo for the Treatment of Lower Limb Spasticity Caused by Stroke or Traumatic Brain Injury

NCT03992404
View directory record Official record
Conditions
Lower Limb or Combined Lower Limb and Upper Limb Spasticity Due to Stroke or Traumatic Brain Injury
Interventions
NT 201, Placebo
Drug
Lead sponsor
Merz Pharmaceuticals GmbH
Industry
Eligibility
18 Years to 85 Years
Enrollment
603 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
15
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Downey, California + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 18, 2026, 2:40 PM EDT
Completed Phase 4 Interventional Results available

Mixed Methods Investigation of Chronic Facial Paralysis in Individuals With Synkinesis

NCT04148872
View directory record Official record
Conditions
Synkinesis
Interventions
Neuromuscular Retraining Therapy (4 months), Chemodenervation (4 months), Neuromuscular Retraining + Chemodenervation
Other · Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 89 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 29, 2022 · Synced Oct 18, 2026, 2:40 PM EDT
Completed Not applicable Interventional Results available

Evaluation of Four Injectable Neuromodulators in the Glabella Area Glabella Area

NCT05167864
View directory record Official record
Conditions
Cosmetic Techniques
Interventions
Onabotulinumtoxina for Injection, Abobotulinumtoxina for Injection, IncobotulinumtoxinA for Injection, PrabotulinumtoxinA for Injection
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
30 Years to 65 Years · Female only
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 17, 2025 · Synced Oct 18, 2026, 2:40 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Xeomin, Radiesse, and Belotero Facial/Neck Rejuvenational

NCT05039723
View directory record Official record
Conditions
Photoaging
Interventions
Radiesse, Xeomin, Belotero
Drug
Lead sponsor
Main Line Center for Laser Surgery
Other
Eligibility
22 Years and older
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Ardmore, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 7, 2022 · Synced Oct 18, 2026, 2:40 PM EDT
Recruiting Phase 4 Interventional

Xeomin® and Gait Related Mobility After Stroke

NCT04908423
View directory record Official record
Conditions
Stroke
Interventions
Xeomin®
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 79 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 25, 2025 · Synced Oct 18, 2026, 2:40 PM EDT
Completed No phase listed Observational

Attainment of Person-centred Goals After Botulinum Toxin Treatment for Upper Limb Spasticity in Real Life Practice

NCT02454803
View directory record Official record
Conditions
Upper Limb Spasticity
Interventions
Not listed
Lead sponsor
Ipsen
Industry
Eligibility
18 Years and older
Enrollment
1,004 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
5
States / cities
Doral, Florida • Chicago, Illinois • Overland Park, Kansas + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2019 · Synced Oct 18, 2026, 2:40 PM EDT
Completed Phase 2 Interventional Results available

Study to Investigate the Safety and Duration of Effect of Different Botulinum Toxin A (NT 201) Dose Groups Following the Treatment of Glabellar Frown Lines

NCT03806933
View directory record Official record
Conditions
Moderate to Severe Glabellar Frown Lines
Interventions
NT 201
Drug
Lead sponsor
Merz Aesthetics GmbH
Industry
Eligibility
18 Years and older
Enrollment
241 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
5
States / cities
Encino, California • Newport Beach, California • San Diego, California + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 15, 2023 · Synced Oct 18, 2026, 2:40 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of NT 201 (IncobotulinumtoxinA [Xeomin]) in the Treatment of Glabellar Frown Lines

NCT00512135
View directory record Official record
Conditions
Glabellar Lines
Interventions
IncobotulinumtoxinA (Xeomin) (20 units)
Drug
Lead sponsor
Merz Pharmaceuticals GmbH
Industry
Eligibility
18 Years and older
Enrollment
801 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
13
States / cities
Los Angeles, California • Englewood, Colorado • Aventura, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2021 · Synced Oct 18, 2026, 2:40 PM EDT
Withdrawn Early Phase 1 Interventional

BOTOX in Men With Prostate Cancer With Lower Urinary Tract Symptoms(LUTS)/Benign Prostatic Hyperplasia (BPH)

NCT01520441
View directory record Official record
Conditions
Prostate Cancer, Benign Prostatic Hyperplasia, Enlarged Prostate With Lower Urinary Tract Symptoms (LUTS)
Interventions
BOTOX
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
50 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 3, 2015 · Synced Oct 18, 2026, 2:40 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Botulinum Toxin Treatment of Glabellar Lines: Efficacy and Safety Study I

NCT02677298
View directory record Official record
Conditions
Glabellar Frown Lines
Interventions
Botulinum Toxin A, Placebo
Drug
Lead sponsor
Croma-Pharma GmbH
Industry
Eligibility
18 Years to 75 Years
Enrollment
784 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
9
States / cities
Birmingham, Alabama • Encino, California • San Francisco, California + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2025 · Synced Oct 18, 2026, 2:40 PM EDT
Terminated Phase 2 Interventional Results available

IncobotulinumtoxinA for Treatment of Focal Cancer Pain After Surgery and/or Radiation

NCT01931865
View directory record Official record
Conditions
Pain
Interventions
IncobotulinumtoxinA
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 31, 2015 · Synced Oct 18, 2026, 2:40 PM EDT
Completed Phase 1 Interventional

A Study of NT 201 in the Treatment of Enlarged Pores and Excessive Sebum Production in the Face

NCT05784363
View directory record Official record
Conditions
Enlarged Pores, Sebum Production
Interventions
NT 201, Placebo
Drug
Lead sponsor
Merz North America, Inc.
Industry
Eligibility
21 Years to 45 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
3
States / cities
Los Angeles, California • Coral Gables, Florida • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 23, 2024 · Synced Oct 18, 2026, 2:40 PM EDT
Completed Phase 2 Interventional Results available

Botulinum Toxin Injection for the Management of BPH

NCT00451191
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
botulinum toxin type A (BoNT/A)
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
50 Years and older · Male only
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
7
States / cities
Denver, Colorado • Chicago, Illinois • Rochester, Minnesota + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2020 · Synced Oct 18, 2026, 2:40 PM EDT
Recruiting Phase 2 Interventional

IncobotulinumtoxinA for Provoked Vestibulodynia With Overactive Pelvic Floor Muscle Dysfunction

NCT07486830
View directory record Official record
Conditions
Provoked Vestibulodynia
Interventions
Incobotulinum Toxin A, Placebo
Drug
Lead sponsor
Center for Vulvovaginal Disorders
Other
Eligibility
18 Years and older · Female only
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
Washington D.C., District of Columbia • New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Oct 18, 2026, 2:40 PM EDT
Completed Phase 3 Interventional Results available

IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Blepharospasm

NCT00406367
View directory record Official record
Conditions
Blepharospasm
Interventions
incobotulinumtoxinA (Xeomin), Placebo
Drug
Lead sponsor
Merz Pharmaceuticals GmbH
Industry
Eligibility
18 Years to 80 Years
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 15, 2013 · Synced Oct 18, 2026, 2:40 PM EDT
Completed Phase 2 Interventional Results available

Botulinum Toxin A to Treat Arm Tremor

NCT02207946
View directory record Official record
Conditions
Essential Tremor of the Upper Limbs
Interventions
IncobotulinumtoxinA, Placebo
Drug
Lead sponsor
Merz Pharmaceuticals GmbH
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 18, 2021 · Synced Oct 18, 2026, 2:40 PM EDT
Active, not recruiting Phase 2 Interventional

Use of Botulinum Toxin in the Treatment of Androgenic Alopecia

NCT05456087
View directory record Official record
Conditions
Androgenetic Alopecia
Interventions
incobotulinumtoxin A
Drug
Lead sponsor
Zel Skin and Laser Specialists
Other
Eligibility
22 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Edina, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 27, 2024 · Synced Oct 18, 2026, 2:40 PM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Comparison of Escalating Doses of IncobotulinumtoxinA (Xeomin®) in the Treatment of Glabellar Rhytids

NCT01583478
View directory record Official record
Conditions
Skin Aging, Elastosis Senilis
Interventions
incobotulinumtoxinA
Biological
Lead sponsor
The Maas Clinic
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 30, 2014 · Synced Oct 18, 2026, 2:40 PM EDT
Completed Phase 3 Interventional Results available

IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Glabellar Frown Lines

NCT00770211
View directory record Official record
Conditions
Moderate to Severe Glabellar Frown Lines
Interventions
IncobotulinumtoxinA (Xeomin) (20 Units), Placebo
Drug
Lead sponsor
Merz Pharmaceuticals GmbH
Industry
Eligibility
18 Years and older
Enrollment
271 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
8
States / cities
Englewood, Colorado • Aventura, Florida • Coral Gables, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2011 · Synced Oct 18, 2026, 2:40 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Treatment of Moderate to Severe Lateral Canthal Lines and Glabellar Lines Alone or in Combination

NCT04247074
View directory record Official record
Conditions
Glabellar Frown Lines (GL), Lateral Canthal Lines (LCL)
Interventions
botulinum toxin neuromodulator, Placebo
Biological
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
413 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
11
States / cities
Encino, California • Santa Monica, California • West Hollywood, California + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 6, 2023 · Synced Oct 18, 2026, 2:40 PM EDT